News
COVID-19 May Have A Novel Treatment, According To Scientist
Cedars-Sinai researchers have discovered a potential new COVID-19 treatment: a biologic material made from reengineered cell cultures. When tested in human lung cells, scientists discovered that the chemical blocked SARS-CoV-2, the causative agent of COVID-19, from replicating and also...
News
Japan tops CPhI API Quality ranking for second year
CPhI Japan 2022 returns as a SMART event – with live exhibition at the Big Sight Exhibition Center in Tokyo (20-22 April) alongside an online networking platform – as CPhI data confirms the country continues to top global ‘API...
News
UK Regulator Cites CluePoints Solutions in Updated Guidance
CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Risk-Based Quality Management Software for clinical trials, has been cited in the updated Good Clinical Practice (GCP) guidance from the UK’s MHRA, putting the agency´s considerable weight behind CluePoints’...
News
Studying Clinical Decision Support Systems In Mental Illness
Researchers, in a new study, showed that using a clinical decision support system that stimulates doctors to provide personalised informational handouts about a patient's cardiovascular risk and treatment recommendations can dramatically lower heart disease risk for patients with severe...
News
Researchers Take Steps In Developing Regenerated Bone Tissue
According to an announcement made on February 15, 2022, McGill University researchers adopted the Canadian Light Source (CLS) at the University of Saskatchewan to create a unique approach for manufacturing synthetic bone tissue. The discovery comes after more than 30...
News
Novo Nordisk expands research collaboration in novel delivery technologies for biologic medicines
Novo Nordisk announced the expansion of its existing research collaboration in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH).
Since 2015, scientists from Novo Nordisk and the laboratories of Prof. Giovanni...
News
EC approves Boehringer-Lilly’s Jardiance for chronic heart failure
The European Commission (EC) has granted marketing authorisation to Boehringer Ingelheim and Eli Lilly and Company’s Jardiance (empagliflozin) to treat symptomatic chronic heart failure in adult patients.
With the latest development, Jardiance became the first treatment to be approved for...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read